Enzo Biochem, Inc. Quarterly report pursuant to Section 13 or 15(d)

Segment Reporting (Tables)

9 Months Ended

Apr. 30, 2022

Three months ended April 30, 2022	Clinical Services			Products			Therapeutics			Other			Consolidated
Revenues	$	18,630		$	7,592			—			—		$	26,222

Operating costs and expenses:
Cost of revenues		11,180			4,869			—			—			16,049
Research and development		666			458			9			—			1,133
Selling, general and administrative		6,756			2,786			—			1,900			11,442
Legal fee expense		12			10			—			712			734
Total operating costs and expenses		18,614			8,123			9			2,612			29,358

Operating income (loss)		16			(531	)		(9	)		(2,612	)		(3,136	)

Other income (expense):
Interest, net		(2	)		10			—			46			54
Other		15			(2	)		—			(729	)		(716	)
Foreign exchange loss		—			(1,056	)		—			—			(1,056	)
Net income (loss)	$	29		$	(1,579	)	$	(9	)	$	(3,295	)	$	(4,854	)

Depreciation and amortization included above	$	430			224			—			78			732

Share-based compensation included in above:
Selling, general and administrative		38			1			—			119			158
Cost of revenues		4			—			—			—			4
Total	$	42			1			—			119			162

Capital expenditures	$	202			572			—			82			856

Three months ended April 30, 2021	Clinical Services			Products			Therapeutics			Other			Consolidated
Revenues	$	25,018		$	7,779			—			—		$	32,797

Operating costs and expenses:
Cost of revenues		12,733			4,018			—			—			16,751
Research and development		173			643		$	20			—			836
Selling, general and administrative		7,029			2,810			17		$	2,226			12,082
Legal fee expenses		95			10			—			956			1,061
Total operating costs and expenses		20,030			7,481			37			3,182			30,730

Operating income (loss)		4,988			298			(37	)		(3,182	)		2,067

Other income (expense):
Interest, net		(4	)		11			—			53			60
Other		1			2			—			(91	)		(88	)
Foreign exchange loss		—			(33	)		—			—			(33	)
Net income (loss)	$	4,985		$	278		$	(37	)	$	(3,220	)	$	2,006

Depreciation and amortization included above	$	399		$	208		$	—		$	66		$	673

Share-based compensation included in above:
Selling, general and administrative		9			41			—			208			258
Cost of revenues		39			—			—			—			39
Total	$	48		$	41		$	—		$	208		$	297

Capital expenditures	$	1,544		$	180		$	—		$	23		$	1,747

Nine months ended April 30, 2022	Clinical Services			Products			Therapeutics			Other			Consolidated
Revenues – Services and Products	$	62,045		$	24,742			—			—		$	86,787

Operating costs and expenses:
Cost of revenues		34,969			14,191			—			—			49,160
Research and development		762			1,901		$	34			—			2,697
Selling, general and administrative		19,568			8,920			—		$	8,472			36,960
Legal and related expenses		217			23			—			4,621			4,861
Total operating costs and expenses		55,516			25,035			34			13,093			93,678

Operating income (loss)		6,529			(293	)		(34	)		(13,093	)		(6,891	)

Other income (expense):
Interest, net		(7	)		28			—			140			161
Other		69			3			—			(1,283	)		(1,211	)
Foreign exchange (loss)					(1,887	)		—			—			(1,887	)
Net income (loss)	$	6,591		$	(2,149	)	$	(34	)	$	(14,236	)	$	(9,828	)

Depreciation and amortization included above	$	1,286		$	626		$	—		$	226		$	2,138

Share-based compensation included in above:
Selling, general and administrative		74			2			—			961			1,037
Cost of revenues		20			—			—			—			20
Total	$	94		$	2		$	—		$	961		$	1,057

Capital expenditures	$	795		$	1,788		$	—		$	520		$	3,103

Nine months ended April 30, 2021	Clinical Services			Products		Therapeutics			Other			Consolidated
Revenues – Services and Products	$	70,229		$	22,689		—			—		$	92,918

Operating costs and expenses:
Cost of revenues		37,436			11,718		—			—			49,154
Research and development		454			1,868	$	66			—			2,388
Selling, general and administrative		19,552			7,848		50		$	5,659			33,109
Legal and related expenses		191			16		—			3,786			3,993
Total operating costs and expenses		57,633			21,450		116			9,445			88,644

Operating income (loss)		12,596			1,239		(116	)		(9,445	)		4,274

Other income (expense):
Interest		(14	)		29		—			(55	)		(40	)
Other		30			6		—			(91	)		(55	)
Foreign exchange gain					428		—			—			428
Net income (loss)	$	12,612		$	1,702	$	(116	)	$	(9,591	)	$	4,607

Depreciation and amortization included above	$	1,189		$	581	$	—		$	198		$	1,968

Share-based compensation included in above:
Selling, general and administrative		28			73		—			473			574
Cost of revenues		66			—		—			—			66
Total	$	94		$	73	$	—		$	473		$	640

Capital expenditures	$	2,425		$	378	$	—		$	67		$	2,870